News | Blood Testing | September 04, 2018

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patients

Prevencio’s multi-protein, AI-driven HART PAD biomarker test has potential to improve clinical outcomes and reduce costs in the treatment of diabetic patients

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient

September 4, 2018 — Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD) in diabetes mellitus (DM) patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these findings, presented at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive and invasive tests.

The study is follow-on to data presented at the American Diabetes Association (ADA) 2018 Scientific Sessions in June demonstrating Prevencio’s HART CAD and HART CVE tests accurately diagnose coronary artery disease (CAD) and predict the risk for major adverse cardiac events (MACE) in DM patients. Similar to CAD, PAD is commonly due to atherosclerosis, a plaque buildup in the arteries which restricts blood flow.

In this study, researchers assessed the company’s artificial intelligence (AI)-driven HART PAD diagnostic test on patients enrolled in Massachusetts General Hospital’s (MGH) Catheter Sampled Blood Archive in Cardiovascular Disease (CASABLANCA) study. The HART PAD test algorithmically assesses six biomarkers linked to atherosclerosis, as well as a patient’s history of hypertension. In patients with DM, the HART PAD panel had excellent performance for diagnosis of PAD. Using a five-point score, a score of 1 had a 100 percent negative predictive value (NPV) and a score of 5 had a 95 percent positive predictive value (PPV). Additionally, the HART PAD panel was highly accurate in predicting the need for revascularization in patients with PAD. These results were comparable to those patients without DM.

Principal investigator James L. Januzzi, M.D., practicing cardiologist at MGH and professor of medicine at Harvard Medical School, said, “The HART PAD test may allow for the diagnosis and treatment of many more patients with currently undetected PAD. In the clinical setting, these findings could assist physicians to identify peripheral artery disease earlier, provide guideline-recommended care and monitor at-risk patients for vascular complications. We believe HART tests could also play an important role in identifying high-risk patients for enrollment in clinical trials, thereby saving time and lowering overall trial costs.”

PAD affects more than 202 million people worldwide and is often underdiagnosed and undertreated until the disease has reached advanced stages. Patients with DM are at substantial risk of developing PAD. Patients with PAD have increased risk of CAD, heart attack or stroke and, if left untreated, PAD can lead to foot or leg amputation.

For more information: www.prevenciomed.com


Related Content

News | Artificial Intelligence

May 21, 2024 — Anumana, a Cambridge, MA-based artificial intelligence (AI)-driven health technology company and ...

Home May 21, 2024
Home
News | Artificial Intelligence

May 2, 2024 — Artificial intelligence experts at Cedars-Sinai and the Smidt Heart Institute created a dataset with more ...

Home May 02, 2024
Home
News | Artificial Intelligence

May 1, 2024 — In an ischemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer ...

Home May 01, 2024
Home
News | Artificial Intelligence

April 24, 2024 — Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence (AI)-powered medical ...

Home April 24, 2024
Home
News | Artificial Intelligence

April 23, 2024 — A recent study designed and implemented by investigators at Cedars-Sinai found that artificial ...

Home April 23, 2024
Home
News | Artificial Intelligence

April 18, 2024 — Karoo Health, the only operational provider of cardiac value-based care (VBC) enablement with published ...

Home April 18, 2024
Home
News | Artificial Intelligence

April 6, 2024 — Experts from the Smidt Heart Institute at Cedars-Sinai will share new research and participate in more ...

Home April 06, 2024
Home
News | Artificial Intelligence

March 28, 2024 — Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart ...

Home March 28, 2024
Home
News | Artificial Intelligence

March 27 2024 — HeartFlow, Inc., a leader in AI-driven healthcare technology, announced the launch of the DECIDE ...

Home March 27, 2024
Home
Subscribe Now